Health X Platform publishes Q1FY26 results in newspapers on August 8
Health X Platform Limited published its Q1FY26 results in newspapers on August 8, 2026, complying with SEBI Regulation 47. The results show consolidated revenue of ₹44,684.98 lakh and net profit of ₹198.67 lakh, approved by the Board on August 7, 2026.

*this image is generated using AI for illustrative purposes only.
Health X Platform Limited published its unaudited financial results for the quarter ended June 30, 2026, in Business Standard and Ek Din newspapers on August 8, 2026. This publication fulfills the company’s obligation under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure confirms the consolidated net profit of ₹198.67 lakh and total revenue from operations of ₹44,684.98 lakh previously reported, ensuring wider accessibility of financial data for investors and stakeholders.
The Board of Directors had approved these results on August 7, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors J K V S & Co. Chairman and Managing Director Banwari Lal Mittal signed off on the results, which are also available on the company’s website and stock exchange portals via a Quick Response (QR) code.
Financial Performance Highlights
The company’s consolidated revenue from operations grew 50% year-on-year to ₹44,684.98 lakh, up from ₹29,842.82 lakh in Q1FY25. Net profit after tax stood at ₹198.67 lakh, reversing a net loss of ₹1,296.88 lakh in the previous quarter. However, this represents a significant decline from the ₹2,659.21 lakh profit recorded in Q1FY25. Earnings per share (basic and diluted) were ₹0.80, compared to a loss per share of ₹3.51 in Q4FY26 and earnings of ₹7.52 in Q1FY25.
| Particulars: | Q1FY26 (₹ in Lakhs) | Q4FY26 (₹ in Lakhs) | Q1FY25 (₹ in Lakhs) |
|---|---|---|---|
| Total Revenue from Operations | 44,684.98 | 37,378.01 | 29,842.82 |
| Other Income | 1,282.98 | 1,375.96 | 2,538.18 |
| Total Expenses | 45,770.48 | 40,140.45 | 29,362.34 |
| Net Profit/(Loss) After Tax | 198.67 | (1,296.88) | 2,659.21 |
| EPS (Basic/Diluted) | 0.80 | (3.51) | 7.52 |
Standalone results showed a net loss of ₹51.43 lakh for the quarter, compared to a loss of ₹15.20 lakh in the previous quarter and ₹10.95 lakh in Q1FY25. Standalone revenue from operations remained flat at ₹8.00 lakh.
Segment-wise Analysis
The Healthcare Network segment remained the primary revenue driver, contributing ₹41,177.80 lakh to total revenue, a substantial increase from ₹27,853.90 lakh in Q1FY25. However, this segment reported a segment result loss of ₹1,486.95 lakh, narrowing from the ₹2,314.40 lakh loss in the prior quarter. The Financial Services segment generated ₹655.75 lakh in revenue and posted a segment profit of ₹557.18 lakh, up from a loss of ₹500.68 lakh in Q4FY26.
What the Numbers Show
The sequential reversal to profitability in Q1FY26 was significantly aided by non-operating factors. While the Healthcare Network's operational losses narrowed, the overall profit figure includes a tax credit of ₹48.94 lakh against current tax expenses of ₹47.75 lakh. Furthermore, the 'Others' segment contributed ₹2,851.43 lakh in revenue with a profit of ₹54.82 lakh, indicating diversification efforts are yielding returns. However, investors should note that the standalone entity continues to incur losses, highlighting that the group-level profitability is currently sustained by its subsidiaries' performance rather than the holding company's core operations.
Corporate Developments and Disclosures
The Board had previously approved a Composite Scheme of Arrangement and Amalgamation involving Health X Platform Limited, Microsec Resources Private Limited, Innogrow Technologies Limited, and Sastasundar Healthbuddy Limited, with an appointed date of April 01, 2026. No accounting effect has been given in the Q1FY26 results pending requisite approvals. The company incurred ₹14.75 lakh in expenses related to this scheme during the quarter.
Statutory auditors J K V S & Co highlighted a material uncertainty regarding the going concern status of step-down subsidiary Genu Path Labs Limited (GPLL). GPLL's net worth has completely eroded, and its current liabilities exceed current assets. Despite this, GPLL's financials have been prepared on a going concern basis, supported by assurances of continued financial support from Sastasundar Healthbuddy Limited.
Historical Stock Returns for Health X Platform
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.21% | -0.78% | -4.31% | +5.93% | +9.91% | +4.75% |
How will the pending Composite Scheme of Arrangement and Amalgamation impact Health X Platform's consolidated financial structure and operational synergies once regulatory approvals are secured?
Given the material uncertainty regarding Genu Path Labs Limited's going concern status, what specific contingency plans or capital injection strategies does the parent company have to prevent potential write-offs?
With standalone operations continuing to report losses while subsidiaries drive group profitability, what strategic initiatives is the holding company undertaking to improve its core operational efficiency?


































